Secondary outcome: acceptability of treatment · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Child‐related outcomes · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression severity (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
2 findings from 1 review
no estimate extracted
Studies not reported
Low
no estimate extracted
Studies not reported
Low
Acceptability ‐ total dropouts · women of any age, with PND up to 12 months
Antidepressants showed no clear difference in treatment acceptability ‐ dropouts compared with placebo (low certainty).
1 finding from 1 review
RR 1.1 [0.74, 1.64]
Studies not reported
Low
Child‐related outcomes · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression response or remission (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · women of any age, with PND up to 12 months
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report and clinician‐rated scales (SOMS‐7, SCL‐90 Somatisation Score) · somatoform disorders in adults
1 finding from 1 review
Acceptability · somatoform disorders in adults
Antidepressants showed no clear difference in acceptability (all‐cause drop‐outs4) compared with a combination of medications (low certainty).
1 finding from 1 review
Anxiety · somatoform disorders in adults
1 finding from 1 review
Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HDRS, BDI) · somatoform disorders in adults
1 finding from 1 review
Withdrawals due to adverse events · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment response (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropout · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout ‐ All studies objective compared with placebo according to any definition (low certainty).
1 finding from 1 review
Severity of depression continuous measures ‐ HDRS total score at the end of the treatment · patients with depression during opioid agonist treatment for opioid dependence
1 finding from 1 review
Adverse events ‐ Withdrawn for medical reasons · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants probably leads to higher adverse events ‐ Withdrawn for medical reasons compared with placebo (moderate certainty).
1 finding from 1 review
Dropout ‐ Studies with low risk of bias · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in dropout ‐ Studies with low risk of bias compared with placebo according to any definition (high certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants showed no clear difference in severity of depression dichotomous measures ‐ >50% reduction in… compared with placebo according to any definition (low certainty).
1 finding from 1 review
Severity of depression dichotomous measures ‐ "very much" or "much" improved on the Clinical Global Impression Scale · patients with depression during opioid agonist treatment for opioid dependence
Antidepressants may leads to higher severity of depression dichotomous measures ‐ "very much" or "much"… compared with placebo according to any definition (low certainty).
1 finding from 1 review